1-Fluoro-2-(4-propan-2-ylphenyl)benzene | 54245-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Fluoro-2-(4-propan-2-ylphenyl)benzene
• CAS: 54245-73-7
• 化学式: C₁₅H₁₅F
• 分子量: 214.283
• InChiKey: UMWKUYTXYIISIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-[4-(2-氟苯基)苯基]乙酮 在 palladium on activated charcoal 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 1-Fluoro-2-(4-propan-2-ylphenyl)benzene
  参考文献：
  名称：

  FR2231393

  摘要：

  公开号：

文献信息

• Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
  申请人：Ralston Stuart Hamilton

  公开号：US20080119555A1

  公开（公告）日：2008-05-22

  The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formula: wherein: Ar 1 is independently C 5-20 aryl (e.g., biphenyl, phenanthryl, fluorenyl, or carbazolyl, most preferably biphenyl), and is optionally substituted; R N is independently —H, acyl, C 5-20 aryl-C 1-7 alkyl, C 3-20 heterocyclyl, or C 1-7 alkyl, and is optionally substituted; R alk is a C 2-10 alkylene group, and is optionally substituted; and Q is independently —H or an organic group having from 1 to 30 atoms selected from carbon, nitrogen, oxygen, sulfur, phosphorus, fluorine, chlorine, bromine, and iodine (e.g., an oxy-type group, an amine-type group, etc.); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

  本发明涉及某些芳基烷基磺酰胺及其衍生物，其中，它们抑制破骨细胞的存活、形成和/或活性；和/或抑制骨吸收，更具体地说，是式子的化合物： 其中：Ar1独立地是C5-20芳基（例如，联苯、菲、芴或咔唑基，最好是联苯），并且可以选择性地被取代；RN独立地是-H、酰基、C5-20芳基-C1-7烷基、C3-20杂环基或C1-7烷基，并且可以选择性地被取代；Ralk是C2-10烷基链，可以选择性地被取代；Q独立地是-H或具有1-30个由碳、氮、氧、硫、磷、氟、氯、溴和碘选择的有机基团（例如，氧型基团，胺型基团等）；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这样的化合物的制药组合物，以及在体外和体内使用这样的化合物和组合物来抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导和/或通过骨吸收表征的骨疾病的治疗，例如骨质疏松症、类风湿性关节炎、与癌症相关的骨疾病、帕吉特病等；和/或用于治疗与炎症或免疫系统激活有关的疾病。
• Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
  申请人：Ralston Hamilton Stuart

  公开号：US20070027112A1

  公开（公告）日：2007-02-01

  The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae: (1) (2) wherein: Ar 1 is independently a biphenyl, phenanthryl, fluorenyl, or carbazolyl, and is optionally substituted; R alk is independently a C 2-10 alkylene group, and is optionally substituted; —OR O , if present, is independently —OH or —OR K ; —OR K , if present, is independently selected from: —O—R K1 ; —O—C(═O)R K2 ; —O—C(═O)OR K3 ; —O—S(═O)2OR K4 ; Q is independently —OH or —OR OT ; wherein: —OR OT , if present, is independently selected from: —O—R E1 ; —O—C(═O)—R E2 ; —O—C(═O)—O—R E3 ; —O—C(═O)—O—SO 3 R E4 ; —O—C(═O)—O—(CH 2 ) n —COOR E5 ; —O—C(═O)—(CH 2 ) n —NR N1 R N2 ; —O—C(═O)—(CH 2 ) n —NH—C(═O)R E6 ; —O—C(═O)—(CH 2 ) n —C(═O)—NR N3 R N4 ; —O—P(═O)(OR E7 )(OR E8 ); —O—R PA ; R PA , if present, is an organic group which incorporates a phosphonic acid group; with the proviso A that if —OR OT is —O—R E1 , then R E1 is not a phenyl group substituted with a sulfonyl group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, or prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

  本发明涉及某些酮和还原酮及其衍生物，其中包括抑制破骨细胞的存活、形成和/或活性；和/或抑制骨吸收的化合物，更具体地说，是以下式子的化合物：（1）（2） 其中：Ar1独立地是联苯基，菲基，芴基或咔唑基，且可以被取代；Ralk独立地是C2-10烷基，且可以被取代；-ORO，如果存在，则独立地是-OH或-ORK；-ORK，如果存在，则独立地选自：-O-RK1；-O-C（═O）-RK2；-O-C（═O）-ORK3；-O-S（═O）2ORK4；Q独立地是-OH或-OROT；其中：-OROT，如果存在，则独立地选自：-O-RE1；-O-C（═O）-RE2；-O-C（═O）-O-RE3；-O-C（═O）-O-SO3RE4；-O-C（═O）-O-（CH2）n-COORE5；-O-C（═O）-（ ）n-NRN1RN2；-O-C（═O）-（ ）n-NH-C（═O）RE6；-O-C（═O）-（ ）n-C（═O）-NRN3RN4；-O-P（═O）（ORE7）（ORE8）；-O-RPA；如果存在RPA，则是包含膦酸基的有机基团；但前提是如果-OROT是-O-RE1，则RE1不是取代有磺酰基的苯基；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式或前药。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是在体内还是体外，以抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导和/或特征为骨吸收的疾病，如骨质疏松症、类风湿性关节炎、癌症相关骨病、帕吉特病、假体松动等；和/或用于治疗与炎症或免疫系统激活相关的疾病。
• KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS
  申请人：RALSTON Stuart H.

  公开号：US20080312186A1

  公开（公告）日：2008-12-18

  The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae and pharmaceutically acceptable salts, amides, esters, and ethers thereof, wherein: Ar1, R alk , —ORO, and -Q are as defined herein: The present invention also pertains to pharmaceutical compositions comprising such compounds. The compounds inhibit osteoclast survival, formation, and/or activity, and inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, and are useful in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

  本发明涉及某些酮和还原酮及其衍生物，其中包括抑制破骨细胞的存活、形成和/或活性；和/或抑制骨吸收的化合物，更具体地，涉及以下式子的化合物和其药学上可接受的盐，酰胺，酯和醚，其中：Ar1，Ralk，—ORO和-Q如本文所定义的：本发明还涉及包含这些化合物的药物组合物。这些化合物抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导和/或以骨吸收为特征的疾病，并可用于治疗骨疾病，如骨质疏松症、类风湿性关节炎、与癌症相关的骨疾病、帕吉特病、人工假体无菌松动等；和/或用于治疗与炎症或免疫系统激活相关的疾病。
• Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same
  申请人：Wang Shaomeng

  公开号：US20110184033A1

  公开（公告）日：2011-07-28

  Potent and selective ligands for the dopamine 3 (D 3 ) receptor are disclosed. The D3 receptor ligands have a structural formula (I) wherein X is C═O or SO 2 , R 1 is C 1-6 alkyl, R 2 is aryl, heteroaryl, aryl, —(CH 2 ) 1-3 aryl, or —(CH 2 ) 1-3 heteroaryl, and n is 0 or 1. Methods of using the D 3 receptor ligands in the treatment of diseases and conditions wherein modulation of the D 3 receptor provides a benefit also are disclosed.

  揭示了对多巴胺3（D3）受体具有强效和选择性的配体。D3受体配体具有结构式（I），其中X是C═O或SO2，R1是C1-6烷基，R2是芳基，杂环芳基，芳基，—（CH2）1-3芳基或—（ ）1-3杂环芳基，n为0或1。还揭示了在调节D3受体提供益处的疾病和病况的治疗中使用D3受体配体的方法。
• Aminothiazole derivatives useful as antiviral agents
  申请人：Innovative Molecules GmbH

  公开号：US10590094B2

  公开（公告）日：2020-03-17

  The invention relates to novel compounds of the Formula (I), to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.

  本发明涉及式（I）的新型化合物、其制备方法以及其作为药物，特别是作为抗病毒药物的用途。